Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is the first clinical study of first-line treatment of head and neck squamous cell
carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China,
which explores the new combination therapies urgently needed in clinical practice and lays a
foundation for subsequent studies, with important scientific research significance and
clinical value.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University